Latest News

Poxel Completes Enrollment in Phase 2 NASH Trial for PXL065 (DESTINY-1) in Biopsy-Proven Patients

PXL065 is a new chemical entity derived from pioglitazone, which has shown to retain NASH efficacy without triggering peroxisome proliferator-activated receptor (PPAR)-g-related side effects in preclinical…

Read this Press Release: Poxel Completes Enrollment in Phase 2 NASH Trial for PXL065 (DESTINY-1) in Biopsy-Proven Patients

Poxel to Host Conference Call for First Half 2021 Financial Results on September 23, 2021

LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology,…

Read this Press Release: Poxel to Host Conference Call for First Half 2021 Financial Results on September 23, 2021

Poxel Announces Product Launch in Japan for TWYMEEG® as Treatment for Type 2 Diabetes

LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic…

Read this Press Release: Poxel Announces Product Launch in Japan for TWYMEEG® as Treatment for Type 2 Diabetes
Click here to show the previous slide Click here to show the next slide

Innovative Pipeline of First-In-Class Products

Our candidates are based on disease-modifying mechanisms of action that offer the potential for safer and more effective therapies for NASH and rare metabolic diseases.

View Pipeline
Innovative Pipeline of First-In-Class Products

Targeting Mitochondrial Dysfunction

Imeglimin was approved as TWYMEEG® for type 2 diabetes in Japan in June 2021 and will be marketed by our strategic partner, Sumitomo Dainippon Pharma, in 2021. Imeglimin has successfully completed Phase 2 development in the U.S. and EU. PXL770 and PXL065 are in mid-stage development for NASH. We are also evaluating our AMPK activation and TZD platforms for other chronic and rare metabolic diseases.

View Our Candidates
Targeting Mitochondrial Dysfunction

Backed by Strong Leadership

Our highly-experienced clinical and regulatory teams possess the know-how and experience to successfully develop products within our pipeline.

Meet Our Team
Backed by Strong Leadership